Polyp Size Measurement at CT Colonography: What Do We Know and What Do We Need to Know?

被引:55
|
作者
Summers, Ronald M. [1 ]
机构
[1] NIH, Imaging Biomarkers & Comp Aided Diag Lab, Dept Radiol & Imaging Sci, Ctr Clin, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
COMPUTED TOMOGRAPHIC COLONOGRAPHY; COLONIC POLYPS; COLORECTAL-CANCER; VIRTUAL COLONOSCOPY; HYPERPLASTIC POLYPS; NATURAL-HISTORY; IN-VITRO; AUTOMATED MEASUREMENT; AMERICAN-COLLEGE; NATIONAL POLYP;
D O I
10.1148/radiol.10090877
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Polyp size is a critical biomarker for clinical management. Larger polyps have a greater likelihood of being or of becoming an adenocarcinoma. To balance the referral rate for polypectomy against the risk of leaving potential cancers in situ, sizes of 6 and 10 mm are increasingly being discussed as critical thresholds for clinical decision making (immediate polypectomy versus polyp surveillance) and have been incorporated into the consensus CT Colonography Reporting and Data System (C-RADS). Polyp size measurement at optical colonoscopy, pathologic examination, and computed tomographic (CT) colonography has been studied extensively but the reported precision, accuracy, and relative sizes have been highly variable. Sizes measured at CT colonography tend to lie between those measured at optical colonoscopy and pathologic evaluation. The size measurements are subject to a variety of sources of error associated with image acquisition, display, and interpretation, such as partial volume averaging, two-versus three-dimensional displays, and observer variability. This review summarizes current best practices for polyp size measurement, describes the role of automated size measurement software, discusses how to manage the measurement uncertainties, and identifies areas requiring further research.
引用
收藏
页码:707 / 720
页数:14
相关论文
共 50 条
  • [1] Update on heparin: what do we need to know?
    Weitz, Daniel S.
    Weitz, Jeffrey I.
    JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2010, 29 (02) : 199 - 207
  • [2] Tumour budding in colorectal cancer: what do we know and what can we do?
    Linde De Smedt
    Sofie Palmans
    Xavier Sagaert
    Virchows Archiv, 2016, 468 : 397 - 408
  • [3] Tumour budding in colorectal cancer: what do we know and what can we do?
    De Smedt, Linde
    Palmans, Sofie
    Sagaert, Xavier
    VIRCHOWS ARCHIV, 2016, 468 (04) : 397 - 408
  • [4] Aberrant crypt foci: What we know and what we need to know
    Gupta, Akshay K.
    Pretlow, Theresa P.
    Schoen, Robert E.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (05) : 526 - 533
  • [5] Assays and applications in warfarin metabolism: what we know, how we know it and what we need to know
    Jones, Drew R.
    Miller, Grover P.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2011, 7 (07) : 857 - 874
  • [6] CT colonography: what radiologists need to know
    Pages Llinas, M.
    Darnell Martin, A.
    Ayuso Colella, J. R.
    RADIOLOGIA, 2011, 53 (04): : 315 - 325
  • [7] Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do?
    Vargas-Franco, Jorge W.
    Castaneda, Beatriz
    Redini, Francoise
    Gomez, David F.
    Heymann, Dominique
    Lezot, Frederic
    JOURNAL OF CELLULAR PHYSIOLOGY, 2018, 233 (08) : 5696 - 5715
  • [10] Amyloidogenesis: What Do We Know So Far?
    Alraawi, Zeina
    Banerjee, Nayan
    Mohanty, Srujana
    Kumar, Thallapuranam Krishnaswamy Suresh
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)